MRNA vs VRTX Comparison: AI Score, Valuation, Performance and Upside
Compare Moderna and Vertex by platform technology durability, COVID vaccine revenue decline vs CF monopoly stability, pipeline breadth, cash runway, and which biotech approach offers better long-term investment returns.
Use this Moderna vs Vertex comparison to evaluate the key differences across valuation, growth, profitability, and risk before making an investment decision.
VRTX holds the edge across 4 of 5 key metrics in this comparison. MRNA has delivered stronger 1-year price return (+106.19% vs +1.36%), though VRTX has the better forward P/E setup (22.36x vs -11.37x for MRNA). VRTX leads on both revenue growth (7.80%) and operating margin (38.13%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for VRTX (+16.77%) than for MRNA (-9.75%).
| Metric | MRNA | VRTX |
|---|---|---|
| AI score | 42.0 | 50.7 |
| AI rank | #876 | #433 |
| Latest close | $56.99 | $478.71 |
| 1M return | -28.55% | -9.34% |
| 6M return | +35.05% | +2.81% |
| 1Y return | +106.19% | +1.36% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | MRNA | VRTX |
|---|---|---|
| 1Y ago | $20.75K (+107.5%) started 2025-08-05 | $12.77K (+27.7%) started 2025-08-05 |
| 5Y ago | $1.38K (-86.2%) started 2021-08-06 | $23.86K (+138.6%) started 2021-08-06 |
| 10Y ago | $30.64K (+206.4%) started 2018-12-07 | $46.72K (+367.2%) started 2016-08-08 |
Hypothetical — past performance does not guarantee future results.
| Metric | MRNA | VRTX |
|---|---|---|
| Market cap | $21.75B | $121.09B |
| Trailing P/E | N/A | 28.33 |
| Forward P/E | -11.37 | 22.36 |
| Price/Sales | N/A | 10.42 |
| EV/Revenue | 8.10 | 9.48 |
| Analyst target | $49.47 | $557.13 |
| Target upside | -9.75% | +16.77% |
| Metric | MRNA | VRTX |
|---|---|---|
| Revenue growth | 2.10% | 7.80% |
| Earnings growth | N/A | 61.40% |
| EPS growth | N/A | +61.40% |
| FCF margin | +13.43% | +22.78% |
| Operating margin | -557.93% | 38.13% |
| Profit margin | -141.43% | 35.51% |
| ROIC proxy | -39.00% | 24.20% |
| Return on equity | -39.00% | 24.20% |
| Dividend yield | N/A | N/A |
| Beta | 0.94 | 0.29 |
| Debt/equity | 19.04 | 10.26 |
| Current ratio | 2.29 | 3.02 |
| Quick ratio | 2.07 | 2.38 |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | MRNA | VRTX |
|---|---|---|---|
| 1Y | Growth | +107.46% | +27.66% |
| CAGR | +107.77% | +27.72% | |
| Sharpe ratio | 1.34 | 0.86 | |
| Max drawdown | 33.90% | 15.21% | |
| Max daily drop | 10.83% | 4.56% | |
| Max wkly drop | 18.08% | 9.32% | |
| 5Y | Growth | -86.22% | +138.55% |
| CAGR | -32.75% | +19.00% | |
| Sharpe ratio | -0.33 | 0.60 | |
| Max drawdown | 95.38% | 29.07% | |
| Max daily drop | 21.01% | 20.60% | |
| Max wkly drop | 33.81% | 20.71% | |
| 10Y | Growth | +206.40% | +367.17% |
| CAGR | +15.74% | +16.68% | |
| Sharpe ratio | 0.50 | 0.50 | |
| Max drawdown | 95.38% | 41.60% | |
| Max daily drop | 21.01% | 20.70% | |
| Max wkly drop | 33.81% | 22.29% |
| Category | MRNA | VRTX |
|---|---|---|
| Company | MRNA | VRTX |
| Sector | Healthcare | Healthcare |
| Industry | N/A | Biotechnology |
| Core business | N/A | N/A |
| Investor focus | N/A | N/A |
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.